The Pharmaceutical Industry versus Medicaid — Limits on State Initiatives to Control Prescription-Drug Costs
- 5 February 2004
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (6) , 608-613
- https://doi.org/10.1056/nejmlim035683
Abstract
The need to manage escalating health care costs while maintaining reasonable access to care is becoming the salient challenge in U.S. health care policy. Insurance coverage is patchy and incomplete, and serious problems with access persist. The health care system has not succeeded in controlling expenditures. The cost pressures resulting from technological advances and an aging population are likely to exacerbate the problem of access.Nowhere is concern about cost and access more pressing than in the provision of prescription drugs through state Medicaid programs. Prescription drugs are the fastest-growing component of health care spending.1 Medicaid has been hit hard . . .Keywords
This publication has 7 references indexed in Scilit:
- The Dilemma of MedicaidNew England Journal of Medicine, 2003
- Whither Seniors’ Pharmacare: Lessons From (And For) CanadaHealth Affairs, 2003
- Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?Health Affairs, 2003
- Dilemmas In Regulation Of The Market For PharmaceuticalsHealth Affairs, 2003
- The Efficient Use Of Pharmaceuticals: Does Europe Have Any Lessons For A Medicare Drug Benefit?Health Affairs, 2003
- The Impact Of A National Prescription Drug Formulary On Prices, Market Share, And Spending: Lessons For Medicare?Health Affairs, 2003
- Trends In U.S. Health Care Spending, 2001Health Affairs, 2003